| Patient Characteristics . | |
|---|---|
| Age at diagnosis mean ± SD, N | 64.4 ± 11.8, 230 |
| Female sex—n (%) | 88 (36%) |
| BMI mean ± SD, N | 26.0 ± 5.1, 179 |
| Tumor MGMT promoter methylation—n (%), N | 90 (42%), 217 |
| KPS score at presentation—n (%), N | |
| ≥70% | 150 (65%), 230 |
| <70% | 80 (35%) |
| Surgery type—n (%), N | |
| Biopsy only | 57 (25%), 230 |
| Partial resection | 98 (43%) |
| Complete resection | 75 (33%) |
| Adjuvant therapy received—N (%), N | |
| Adjuvant chemotherapy only | 15 (7%), 228 |
| Adjuvant radiotherapy only | 15 (7%) |
| Adjuvant chemo- and radiotherapy | 167 (73%) |
| None | 31 (14%) |
| No preoperative dexamethasone—N (%) | 2 (0.8%) |
| Preoperative dexamethasone | 228 (99.2%) |
| Postoperative dexamethasone | 229 (99%) |
| Preoperative dexamethasone—median mg (IQR) | 12 (4–16) |
| Postoperative dexamethasone | 11.9 (9.3–14.5) |
| Length of hospital stay (median days IQR), N | 8 (4–17), 222 |
| Time to recurrence | 263 (133–387), 57 |
| Time to progression | 124.5 (82–201), 80 |
| Time to infection | 69 (19.5–112), 58 |
| Time to thrombosis | 60 (30–137), 41 |
| Time to death | 254 (133–457), 199 |
| NLR measurements (median IQR), N | |
| Perioperative NLR | 9 (5–16), 230 |
| Postoperative NLR | 11 (6–19), 169 |
| Positive Δ NLR | 6 (2–12), 94 |
| Patient Characteristics . | |
|---|---|
| Age at diagnosis mean ± SD, N | 64.4 ± 11.8, 230 |
| Female sex—n (%) | 88 (36%) |
| BMI mean ± SD, N | 26.0 ± 5.1, 179 |
| Tumor MGMT promoter methylation—n (%), N | 90 (42%), 217 |
| KPS score at presentation—n (%), N | |
| ≥70% | 150 (65%), 230 |
| <70% | 80 (35%) |
| Surgery type—n (%), N | |
| Biopsy only | 57 (25%), 230 |
| Partial resection | 98 (43%) |
| Complete resection | 75 (33%) |
| Adjuvant therapy received—N (%), N | |
| Adjuvant chemotherapy only | 15 (7%), 228 |
| Adjuvant radiotherapy only | 15 (7%) |
| Adjuvant chemo- and radiotherapy | 167 (73%) |
| None | 31 (14%) |
| No preoperative dexamethasone—N (%) | 2 (0.8%) |
| Preoperative dexamethasone | 228 (99.2%) |
| Postoperative dexamethasone | 229 (99%) |
| Preoperative dexamethasone—median mg (IQR) | 12 (4–16) |
| Postoperative dexamethasone | 11.9 (9.3–14.5) |
| Length of hospital stay (median days IQR), N | 8 (4–17), 222 |
| Time to recurrence | 263 (133–387), 57 |
| Time to progression | 124.5 (82–201), 80 |
| Time to infection | 69 (19.5–112), 58 |
| Time to thrombosis | 60 (30–137), 41 |
| Time to death | 254 (133–457), 199 |
| NLR measurements (median IQR), N | |
| Perioperative NLR | 9 (5–16), 230 |
| Postoperative NLR | 11 (6–19), 169 |
| Positive Δ NLR | 6 (2–12), 94 |
Abbreviations: BMI:, body mass index; IQR, interquartile range; KPS, Karnofsky Performance Scale; MGMT: O6-methylguanine-DNA methyltransferase; NLR, neutrophil-to-lymphocyte ratio; SD, standard deviation.
ΔNLR signifies a change in NLR from preoperative to postoperative NLR values = postoperative NLR—preoperative NLR.
| Patient Characteristics . | |
|---|---|
| Age at diagnosis mean ± SD, N | 64.4 ± 11.8, 230 |
| Female sex—n (%) | 88 (36%) |
| BMI mean ± SD, N | 26.0 ± 5.1, 179 |
| Tumor MGMT promoter methylation—n (%), N | 90 (42%), 217 |
| KPS score at presentation—n (%), N | |
| ≥70% | 150 (65%), 230 |
| <70% | 80 (35%) |
| Surgery type—n (%), N | |
| Biopsy only | 57 (25%), 230 |
| Partial resection | 98 (43%) |
| Complete resection | 75 (33%) |
| Adjuvant therapy received—N (%), N | |
| Adjuvant chemotherapy only | 15 (7%), 228 |
| Adjuvant radiotherapy only | 15 (7%) |
| Adjuvant chemo- and radiotherapy | 167 (73%) |
| None | 31 (14%) |
| No preoperative dexamethasone—N (%) | 2 (0.8%) |
| Preoperative dexamethasone | 228 (99.2%) |
| Postoperative dexamethasone | 229 (99%) |
| Preoperative dexamethasone—median mg (IQR) | 12 (4–16) |
| Postoperative dexamethasone | 11.9 (9.3–14.5) |
| Length of hospital stay (median days IQR), N | 8 (4–17), 222 |
| Time to recurrence | 263 (133–387), 57 |
| Time to progression | 124.5 (82–201), 80 |
| Time to infection | 69 (19.5–112), 58 |
| Time to thrombosis | 60 (30–137), 41 |
| Time to death | 254 (133–457), 199 |
| NLR measurements (median IQR), N | |
| Perioperative NLR | 9 (5–16), 230 |
| Postoperative NLR | 11 (6–19), 169 |
| Positive Δ NLR | 6 (2–12), 94 |
| Patient Characteristics . | |
|---|---|
| Age at diagnosis mean ± SD, N | 64.4 ± 11.8, 230 |
| Female sex—n (%) | 88 (36%) |
| BMI mean ± SD, N | 26.0 ± 5.1, 179 |
| Tumor MGMT promoter methylation—n (%), N | 90 (42%), 217 |
| KPS score at presentation—n (%), N | |
| ≥70% | 150 (65%), 230 |
| <70% | 80 (35%) |
| Surgery type—n (%), N | |
| Biopsy only | 57 (25%), 230 |
| Partial resection | 98 (43%) |
| Complete resection | 75 (33%) |
| Adjuvant therapy received—N (%), N | |
| Adjuvant chemotherapy only | 15 (7%), 228 |
| Adjuvant radiotherapy only | 15 (7%) |
| Adjuvant chemo- and radiotherapy | 167 (73%) |
| None | 31 (14%) |
| No preoperative dexamethasone—N (%) | 2 (0.8%) |
| Preoperative dexamethasone | 228 (99.2%) |
| Postoperative dexamethasone | 229 (99%) |
| Preoperative dexamethasone—median mg (IQR) | 12 (4–16) |
| Postoperative dexamethasone | 11.9 (9.3–14.5) |
| Length of hospital stay (median days IQR), N | 8 (4–17), 222 |
| Time to recurrence | 263 (133–387), 57 |
| Time to progression | 124.5 (82–201), 80 |
| Time to infection | 69 (19.5–112), 58 |
| Time to thrombosis | 60 (30–137), 41 |
| Time to death | 254 (133–457), 199 |
| NLR measurements (median IQR), N | |
| Perioperative NLR | 9 (5–16), 230 |
| Postoperative NLR | 11 (6–19), 169 |
| Positive Δ NLR | 6 (2–12), 94 |
Abbreviations: BMI:, body mass index; IQR, interquartile range; KPS, Karnofsky Performance Scale; MGMT: O6-methylguanine-DNA methyltransferase; NLR, neutrophil-to-lymphocyte ratio; SD, standard deviation.
ΔNLR signifies a change in NLR from preoperative to postoperative NLR values = postoperative NLR—preoperative NLR.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
